Molbio Diagnostics Limited

Molbio Diagnostics Limited

MOLBIO.NS
Molbio Diagnostics LimitedIN flagNational Stock Exchange of India
1,110.90
INR
+69.20
- -
139.21BMarket Cap
Molbio Diagnostics Limited
MOLBIO.NS
(National Stock Exchange of India)

Recent

price

1,110.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available
Business
Molbio Diagnostics Limited is a biomedical diagnostics company focused on developing and commercializing rapid molecular testing solutions for infectious diseases and other life-science applications. The company delivers a portfolio of products and services designed to enable rapid, accurate, point-of-care and centralized laboratory testing, with an emphasis on simplifying workflows, reducing turnaround times, and enabling scalable deployment across diverse settings. Main products and services: advanced molecular diagnostic assays and kits for pathogen detection; real-time PCR and isothermal amplification platforms; consumables and reagents including primers, probes, and reaction buffers; integrated testing workflows and sample-to-answer solutions; validation, quality control materials, and proficiency testing services; software and data analytics tools for result interpretation, monitoring, and reporting; contract research and development (R&D) services; regulatory and compliance support including validation documentation and regulatory submissions. Latest major company changes: strategic partnerships and collaborations to expand assay menu and validate new targets; recent funding rounds and/or acquisitions to strengthen product pipeline and manufacturing capability; launches of new diagnostic tests and related platforms; organizational reorganizations to streamline operations and scale up production; expansion of geographic footprint through new partnerships, distributors, and regional manufacturing capabilities; updates to branding or corporate structure reflecting growth. Additional context: operates in the in vitro diagnostic (IVD) industry with segments spanning clinical diagnostics, reference laboratories, and point-of-care testing; targets hospitals, clinics, reference labs, and public health organizations; geographic operations extend to multiple regions with manufacturing and distribution networks; founded with headquarters in India; subsidiaries or parent relationships may exist as part of corporate group structures.